
Epilepsy Drug Market by Product Type (First-Generation Drugs, Second-Generation Drugs, Third-Generation Drugs), Distribution Channel (Hospital Pharmacy, Pharmacy Stores) - Global Forecast 2024-2030
Description
Epilepsy Drug Market by Product Type (First-Generation Drugs, Second-Generation Drugs, Third-Generation Drugs), Distribution Channel (Hospital Pharmacy, Pharmacy Stores) - Global Forecast 2024-2030
The Epilepsy Drug Market size was estimated at USD 4.55 billion in 2023 and expected to reach USD 4.87 billion in 2024, at a CAGR 7.09% to reach USD 7.35 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Epilepsy Drug Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Epilepsy Drug Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Epilepsy Drug Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Densa Pharmaceuticals Pvt. Ltd., Eisai Co., Ltd., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Micro Labs Ltd., Novartis International AG, Pfizer Inc., Psychotropics India Ltd., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Sunovion Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and UCB S.A..
Market Segmentation & Coverage
This research report categorizes the Epilepsy Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:
Product Type
First-Generation Drugs
Ethosuximide
Oxcarbazepine
Phenytoin
Second-Generation Drugs
Felbamate
Lamotrigine
Topiramate
Third-Generation Drugs
Eslicarbazepine Acetate
Lacosamide
Ralfinamide
Distribution Channel
Hospital Pharmacy
Pharmacy Stores
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Epilepsy Drug Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Epilepsy Drug Market?
3. What are the technology trends and regulatory frameworks in the Epilepsy Drug Market?
4. What is the market share of the leading vendors in the Epilepsy Drug Market?
5. Which modes and strategic moves are suitable for entering the Epilepsy Drug Market?PDF E-mail From Publisher (2-5)Users License
Table of Contents
184 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Epilepsy Drug Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Growing prevalences of epilepsy
- 5.1.1.2. Rising incidence of neurological disorders, birth-related injuries, and traffic injuries
- 5.1.1.3. Rising investment and support from the government
- 5.1.2. Restraints
- 5.1.2.1. Lack of infrastructure and scarcity of treatment for epilepsy
- 5.1.3. Opportunities
- 5.1.3.1. Rising drug approvals of anticonvulsant drugs from regulatory bodies
- 5.1.3.2. Penetration of collaboration and product launch activities
- 5.1.4. Challenges
- 5.1.4.1. Side effects associated with the drugs
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Epilepsy Drug Market, by Product Type
- 6.1. Introduction
- 6.2. First-Generation Drugs
- 6.3.1. Ethosuximide
- 6.3.2. Oxcarbazepine
- 6.3.3. Phenytoin
- 6.3. Second-Generation Drugs
- 6.4.1. Felbamate
- 6.4.2. Lamotrigine
- 6.4.3. Topiramate
- 6.4. Third-Generation Drugs
- 6.5.1. Eslicarbazepine Acetate
- 6.5.2. Lacosamide
- 6.5.3. Ralfinamide
- 7. Epilepsy Drug Market, by Distribution Channel
- 7.1. Introduction
- 7.2. Hospital Pharmacy
- 7.3. Pharmacy Stores
- 8. Americas Epilepsy Drug Market
- 8.1. Introduction
- 8.2. Argentina
- 8.3. Brazil
- 8.4. Canada
- 8.5. Mexico
- 8.6. United States
- 9. Asia-Pacific Epilepsy Drug Market
- 9.1. Introduction
- 9.2. Australia
- 9.3. China
- 9.4. India
- 9.5. Indonesia
- 9.6. Japan
- 9.7. Malaysia
- 9.8. Philippines
- 9.9. Singapore
- 9.10. South Korea
- 9.11. Taiwan
- 9.12. Thailand
- 9.13. Vietnam
- 10. Europe, Middle East & Africa Epilepsy Drug Market
- 10.1. Introduction
- 10.2. Denmark
- 10.3. Egypt
- 10.4. Finland
- 10.5. France
- 10.6. Germany
- 10.7. Israel
- 10.8. Italy
- 10.9. Netherlands
- 10.10. Nigeria
- 10.11. Norway
- 10.12. Poland
- 10.13. Qatar
- 10.14. Russia
- 10.15. Saudi Arabia
- 10.16. South Africa
- 10.17. Spain
- 10.18. Sweden
- 10.19. Switzerland
- 10.20. Turkey
- 10.21. United Arab Emirates
- 10.22. United Kingdom
- 11. Competitive Landscape
- 11.1. FPNV Positioning Matrix
- 11.2. Market Share Analysis, By Key Player
- 11.3. Competitive Scenario Analysis, By Key Player
- 12. Competitive Portfolio
- 12.1. Key Company Profiles
- 12.1.1. Abbott Laboratories
- 12.1.2. Densa Pharmaceuticals Pvt. Ltd.
- 12.1.3. Eisai Co., Ltd.
- 12.1.4. GlaxoSmithKline PLC
- 12.1.5. Johnson & Johnson Services, Inc.
- 12.1.6. Micro Labs Ltd.
- 12.1.7. Novartis International AG
- 12.1.8. Pfizer Inc.
- 12.1.9. Psychotropics India Ltd.
- 12.1.10. Sanofi S.A.
- 12.1.11. Sun Pharmaceutical Industries Ltd.
- 12.1.12. Sunovion Pharmaceuticals, Inc.
- 12.1.13. Teva Pharmaceutical Industries Ltd.
- 12.1.14. Torrent Pharmaceuticals Ltd.
- 12.1.15. UCB S.A.
- 12.2. Key Product Portfolio
- 13. Appendix
- 13.1. Discussion Guide
- 13.2. License & Pricing
- FIGURE 1. EPILEPSY DRUG MARKET RESEARCH PROCESS
- FIGURE 2. EPILEPSY DRUG MARKET SIZE, 2023 VS 2030
- FIGURE 3. EPILEPSY DRUG MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. EPILEPSY DRUG MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. EPILEPSY DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. EPILEPSY DRUG MARKET DYNAMICS
- FIGURE 7. EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
- FIGURE 8. EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
- FIGURE 10. EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. AMERICAS EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 12. AMERICAS EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 14. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 16. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. EPILEPSY DRUG MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 20. EPILEPSY DRUG MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.